Fluzoparib with apatinib vs chemo for advanced breast cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two oral targeted drugs (fluzoparib and apatinib) against standard chemotherapy for women with advanced, HRD-positive, HER2-negative breast cancer. It may be an option if you have already received some treatments but not too many.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old with breast cancer that has spread to other parts of the body.
- Your cancer is HER2-negative (a type of breast cancer) and has a positive HRD test (meaning your tumor has trouble repairing DNA).
- You have already received endocrine therapy (hormone treatment) if your cancer is hormone receptor positive.
- You have had no more than two types of chemotherapy for your advanced cancer, and your last treatment helped your cancer shrink or stay stable for at least 6 months.
- You are in reasonably good health otherwise, with normal blood counts, liver and kidney function, and no serious heart problems.
- You are not pregnant and agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking fluzoparib (a PARP inhibitor) plus apatinib (a targeted therapy) after initial chemotherapy can help keep advanced ovarian, fallopian tube, or primary peritoneal cancer from coming back. It is for people who have finished their first treatment and are in good overall health.
This trial tests adding apatinib to a doctor-chosen standard treatment for advanced, hormone receptor-positive breast cancer that is HER2-negative. The goal is to see if this combination slows cancer growth in patients who have progressed after endocrine therapy and CDK4/6 inhibitors.
This trial tests a combination of two oral drugs (fluzoparib and apatinib) as maintenance therapy after chemotherapy for women with relapsed ovarian cancer. It might help keep the cancer from coming back for those who have already responded well to platinum-based chemo.
This trial tests a combination of two oral drugs—fuzuloparib (a PARP inhibitor) and apatinib (which blocks blood vessel growth to tumors)—given before surgery for advanced ovarian cancer that cannot be removed right away. It is for people whose tumors have a specific genetic marker (HRD positive) and who have not had prior cancer treatment.
This trial tests a combination of two drugs, apatinib and a CDK4/6 inhibitor, as the first treatment for a specific type of advanced breast cancer that is HR+ and HER2-. It's designed for people with the 'SNF4' subtype, which is identified by a special analysis of your tumor sample.
This Phase 2 study tests whether apatinib combined with a CDK4/6 inhibitor and hormone therapy can better control advanced hormone receptor–positive, HER2-negative breast cancer. It may help shrink tumors or slow their growth, especially in cases that can’t be fully treated with surgery or radiation.
Hear when a new Fludzoparib" and Anti-angiogenic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.